NTRA
NateraCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The primary-source earnings package supports a still-positive post-print read: revenue growth stayed near 39%, guidance moved higher, gross margin improved, oncology volume remained very strong, and cash generation stayed positive. Secondary post-print coverage on May 8, 2026 showed multiple target increases, including Evercore to $270, Baird to $265, and JPMorgan to $265, which is directionally consistent with a favorable earnings revision signal.
Posture
Mixed
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-06-03.
What can break
2026 guidance calls for R&D of $800M-$900M, up from the prior range, reflecting accelerated clinical-trial and product investment that could pressure near-term profitability even if it supports long-run platform value [#8-K-2026-05-07].
Momentum
45
Value
48
Sentiment
62
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $245.00 · Bull $285.00 · Bear $185.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $262.19
Why
Momentum45 · Δ7d +10.8
Value48 · Δ7d +0.0
Sentiment62 · Δ7d -5.4
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
45
34% active weight
Current posture
7d trendImproving
Δ7d
+10.8
Δ21d
+10.8
Value
48
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
62
33% active weight
Current posture
7d trendSoftening
Δ7d
-5.4
Δ21d
-2.3
Why this grade
Composite grade C. Momentum 44.9 / Value 48.4 / Sentiment 61.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$30.47B
Beta
1.63
Shares Out
139.14M
P/E (TTM) · Derived
-143.8
P/S (TTM)
15.61
P/FCF (TTM)
353.07
Rev YoY
+34.7%
EPS YoY
-150.0%
Gross Margin
+63.7%
Op Margin
-16.6%
Net Debt
-$887.91M
Current Ratio
3.27
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology